GSK and J&J alum Vi­jay Red­dy to take con­trol of R&D at Tmu­ni­ty; An­drew Hirsch ex­its Agios for CEO job at C4 Ther­a­peu­tics

→ Vi­jay Red­dy was seek­ing a re­turn to the US when he left his role as CMO at Lon­don-based Au­to­lus this sum­mer. Philadel­phia is that land­ing spot, as the T cell im­munother­a­py play­er Tmu­ni­ty has put him in charge of R&D.

Red­dy ar­rives at the Penn spin­out with plen­ty of Big Phar­ma bona fides af­ter de­vel­op­ing the CAR-T cell clin­i­cal pro­gram at Au­to­lus. Tmu­ni­ty’s new chief R&D of­fi­cer was a se­nior di­rec­tor and led ear­ly clin­i­cal de­vel­op­ment at J&J sub­sidiary Janssen from 2013-16, and from 2009-13, he was GSK’s med­ical di­rec­tor, can­cer re­search and clin­i­cal de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER